Phase I clinical trial of intracerebroventricular transplantation of allogeneic neural stem cells in people with progressive multiple sclerosis-Reference-Cited by-同舟云学术

Phase I clinical trial of intracerebroventricular transplantation of allogeneic neural stem cells in people with progressive multiple sclerosis

Published:2023-12 Issue:12 Volume:30 Page:1597-1609.e8
ISSN:1934-5909
Container-title:Cell Stem Cell
language:en
Short-container-title:Cell Stem Cell

Author:

Leone Maurizio A.,Gelati Maurizio,Profico Daniela C.,Gobbi Claudio,Pravatà Emanuele,Copetti Massimiliano,Conti Carlo,Abate Lucrezia,Amoruso Luigi,Apollo Francesco,Balzano Rosario F.,Bicchi Ilaria,Carella Massimo,Ciampini Alessandro,Colosimo Carlo,Crociani Paola,D’Aloisio Giada,Di Viesti Pietro,Ferrari Daniela,Fogli Danilo,Fontana Andrea,Frondizi Domenico,Grespi Valentina,Kuhle Jens,Laborante Antonio,Lombardi Ivan,Muzi Gianmarco,Paci Francesca,Placentino Giuliana,Popolizio Teresa,Ricciolini Claudia,Sabatini Simonetta,Silveri Giada,Spera Cristina,Stephenson Daniel,Stipa Giuseppe,Tinella Elettra,Zarrelli Michele,Zecca Chiara,Ventura Yendri,D’Alessandro Angelo,Peruzzotti-Jametti Luca,Pluchino Stefano^ORCID,Vescovi Angelo L.

Funder

Wellcome Trust

Ministero della Salute

National Cancer Institute

University of Colorado

Publisher

Elsevier BV

Subject

Cell Biology,Genetics,Molecular Medicine

Reference44 articles.

1. A global perspective on the burden of multiple sclerosis;Stenager;Lancet Neurol.,2019

2. Advances in oral immunomodulating therapies in relapsing multiple sclerosis;Derfuss;Lancet Neurol.,2020

3. Onset of secondary progressive phase and long-term evolution of multiple sclerosis;Scalfari;J. Neurol. Neurosurg. Psychiatry,2014

4. Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis;Brown;JAMA,2019

5. Ocrelizumab-treated patients with relapsing multiple sclerosis show volume loss rates similar to healthy aging;Kolind;Mult. Scler.,2023